Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation
Phosplatin Therapeutics To present translational research in hematological malignancies at the ASH 2017 Annual Meeting. Click here to access the public abstract
Phosplatin Therapeutics announces Collaboration with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate Combination of PT-112 and Avelumab in Phase I / II Studies
Phosplatin Therapeutics presents data from its Phase I study of PT-112, selected for an oral discussion session at the ASCO 2017 Annual Meeting. Click here to access the public abstract
Phosplatin therapeutics to present along with the Institute of cancer research montpellier at the AACR 2017 Annual meeting
Phosplatin Therapeutics presents at the 38th EORTC-pamm Meeting (the pharmacology & molecular mechanisms group of the EORTC)
Phosplatin Therapeutics' research findings Presented at the 2016 AACR-NCI-EORTC International conference on Molecular Targets and cancer therapeutics
phosplatin therapeutics shares announcement on the launch of a combination clinical trial of PT-112 in Taiwan under Greater China collaboration agreement with sciclone pharmaceuticals
PHOSPLATIN THERAPEUTICS ANNOUNCES ITS COLLABORATION AND OPTION AGREEMENT FOR RIGHTS TO PT-112 IN GREATER CHINA
Phosplatin Therapeutics saddened by the death of the inventor of phosphaplatins, Rathindra N. Bose, PhD.
Phosplatin Therapeutics Announces the appointment of jose jimeno, MD, PhD as its chief medical officer
Phosplatin Therapeutics announces launch of Phase I clinical trial
